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In this issue of the Journal, Holland et al. (1) provide a
valuable contribution to the literature by reporting the first
meta-analysis of medication trials for heart failure (HF)
with preserved ejection fraction (HFpEF). This work is
important, since HFpEF is the most common and fastest
growing form of HF in the United States (2). The prognosis
for HFpEF is worsening, while it is improving for HF with
reduced ejection fraction (HFREF) (2). The burden on
patients and society from HFpEF is similar to that from
HFREF, measured by healthcare costs (3), rehospitaliza-
tions, mortality after hospitalization, exercise intolerance,
and quality of life (4–6). Despite its importance, there are
large gaps in our understanding of the pathophysiology and
treatment of HFpEF. This is demonstrated by a review
of the current American College of Cardiology/American
Heart Association statement on management of HF. There
are 21 pages discussing HFREF treatments supported by
definitive trials, but just 3 paragraphs regarding HFpEF (7).
See page 1676
By pooling data from reported treatment trials, Holland
et al. (1) help fill this chasm. Their meta-analysis focuses on
the key outcomes in HF: exercise intolerance, hospitaliza-
tions, and death. The authors conclude that medical treat-
ments may improve exercise intolerance, but not mortality.
They rightly highlight that this is still an important benefit,
since exercise capacity is a strong determinant of health-
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advanced in age (5). In older persons, it can be a more
important and achievable goal to “add life to the remaining
years than to add years to the remaining life” (8). Another
conclusion to add is that there were no negative trends in
any outcomes, giving reassurance when these medications
are needed for other indications in HFpEF patients (9).
Holland et al. (1) point out that our work is far from
finished, noting that their conclusions regarding exercise
capacity are based on data from only 183 total treated
patients drawn from 6 trials. Further, if one excludes the
largest trial, which enrolled elderly men after myocardial
infarction with EF as low as 40%, then more than one-third
of the remaining patients were drawn from a single, ade-
quately powered study that was decidedly neutral (10). This
is potentially consequential because, as Holland et al. (1)
highlight, there can be substantial bias against publication of
trials, particularly smaller ones, that have neutral or negative
results. This creates an important unknown in meta-
analyses. In addition, the few available studies did not allow
Holland et al. (1) to examine whether there are differences
between medication classes. Thus, while this timely meta-
analysis supports a positive trend, additional trials focused
on the important outcome of exercise capacity in HFpEF
are needed.
Holland et al. (1) report 2 findings that seem to contra-
dict conventional wisdom. The first is that improvements in
exercise capacity among HFpEF patients have not been
accompanied by improvements in mortality. Numerous
observational studies indicate that exercise capacity and
survival are closely related in HF patients. However, a lesson
learned during the 5-decades-old quest to determine opti-
mal therapy for HFREF is that treatment effects on exercise
capacity and survival can diverge (11). For example, ino-
tropes produced the most potent improvements in exercise
capacity but uniformly worsened survival (12). Renin-
angiotensin-aldosterone inhibitors produced only small im-
provements in exercise capacity, but large improvements
in survival (13). Beta-adrenergic blockers can acutely
worsen exercise capacity, but produced the largest im-
provements in survival (14). This divergence in treatment
effects in HFREF has not been fully explained, and is
frequently forgotten, only to be remembered when a prom-
ising new drug shows the same pattern (11). Therefore, for
HF, theoretical models regarding mortality based on exer-
cise pathophysiology eventually need testing in large clinical
trials. However, that does not diminish the value of exercise
capacity as an independently important clinical endpoint in
HFpEF (15–17).
The second paradox reported by Holland et al. (1) is the
lack of improvement in resting diastolic function despite
significant improvements in exercise capacity. Because ex-
ercise intolerance is the central nonfatal outcome of chronic
HF, this might give us pause to consider whether diastolic






















1688 Kitzman JACC Vol. 57, No. 16, 2011
Heart Failure With Preserved Ejection Fraction Arpil 19, 2011:1687–9treatment should be targeted. Indeed, a second often-
forgotten lesson from the legacy of HFREF trials is that the
pathophysiology of exercise intolerance is complex and
rarely explained by a single abnormality, no matter how
obvious or compelling. For instance, reduced EF, the most
obvious abnormality in HFREF, was found to correlate
poorly with exercise capacity (18). Increased pulmonary
artery wedge pressure, the other compelling cardiac abnor-
mality, correlated relatively modestly with exercise capacity
(18). Instead, the less-apparent peripheral abnormalities,
including abnormal vascular function and abnormal skeletal
muscle function, emerged as strong determinants of reduced
exercise capacity in HFREF (18). That was confirmed by
studies showing that increasing cardiac output by organ
replacement or other means had relatively modest acute
effect on exercise capacity (18).
An important limitation of most HF exercise outcomes
trials, including those that reported diastolic function in the
present meta-analysis, is that mechanistic measurements
were made only at rest. An enduring principle of exercise
physiology is that definitive conclusions regarding mecha-
nisms of exercise intolerance require assessment of candi-
date variables during exercise to test reserve capacity (17).
By the Fick equation, peak exercise oxygen consumption, an
objective measure of exercise capacity, is the product of
cardiac output and arteriovenous oxygen difference. In
healthy subjects the 4-fold increase in oxygen consumption
during exercise is achieved by a 2.5-fold increase in cardiac
output and a 1.5-fold increase in arteriovenous oxygen
difference (19). The increase in cardiac output is achieved
primarily by increased heart rate, whereas stroke volume
increases only about 0.3-fold (19). Thus, absent significant
chronotropic incompetence, peripheral vascular and skeletal
muscle abnormalities would be expected to be candidates for
a role in severely reduced exercise capacity. Yet, work to date
on HFpEF has focused predominantly on factors that
influence stroke volume, with little focus on peripheral
abnormalities. Remembering these 2 important lessons
from HFREF research and understanding exercise physiol-
ogy principles may facilitate a more direct and expeditious
route in the discovery process for HFpEF treatments.
This discussion leads us to examine 2 suggestions made
by Holland et al. (1), which are that future trials might be
more fruitful if they select patients with “endorsed” or
“objective” criteria of HFpEF, and select more “homoge-
nous” samples. The first of the endorsed criteria, a normal
range EF, is logical to avoid overlap with HFREF. The 2
other main endorsed criteria are abnormal diastolic function
and brain natriuretic peptide (BNP). However, as discussed
in the preceding text, current studies indicate that improve-
ments in outcomes can occur with no change in measures of
resting diastolic function. Furthermore in HFREF, ino-
tropes that specifically targeted low EF, the most obvious
cardiac abnormality, paradoxically increased mortality.
Thus, it is not assured that a pure “lusitrope” would be the
“magic bullet” for HFpEF. Increased BNP has good per-formance characteristics in acutely decompensated patients.
However, traditional trials, such as those in this meta-
analysis, focus on stable, ambulatory outpatients in whom
BNP levels should be lower (5,10,20,21) Furthermore, BNP
levels tend to be lower in obese persons, and are less specific
among women and the elderly, all of which are key
characteristics of typical HFpEF in population studies (21).
inally, in I-PRESERVE (Irbesartan in Patients With
eart Failure and Preserved Ejection Fraction), the largest
linical trial of HFpEF to date, treatment effect was
nrelated to BNP level (9). Admittedly, the criteria favored
y Holland et al. (1) have been recommended in a promi-
ent consensus statement and are supported by other
uthorities as well (22). However, they have not been
ystematically tested in prospective population-based studies
f stable, community-dwelling elderly outpatients, but were
eveloped largely on the basis of theoretical models of the
athophysiology of acute HFpEF. The experience in
FREF research illustrates the potential pitfalls of such an
pproach (23).
The other suggestion, to select more homogenous sam-
les, should also be examined. This approach has already
ontributed to the present state where trial-based treatment
uidelines for HF do not apply to the majority of patients
ho actually have the disease (24,25). The typical HFpEF
atient is an elderly woman with multiple comorbidities that
ommonly constitute exclusions in clinical trials (25,26). By
ature, HFpEF is heterogeneous (as is HFREF). Further-
ore, several studies indicate that approximately 50% of
adverse outcomes during long-term follow-up of elderly HF-
pEF patients are noncardiac events, likely driven by their
multiple comorbidities and physical debilitation (9,25–27).
This instructive finding confirms there are important aspects
we do not fully understand regarding the complex pathophys-
iology of HFpEF and suggests avenues for novel intervention
strategies. It also suggests there is merit to the selection criteria
traditionally used for HFpEF: signs and symptoms of HF,
normal range EF, and no obvious alternate or clearly treatable
explanation (20,21,28,29). This approach embraces the com-
plexity and heterogeneity that characterize HFpEF in the
population, and ensures that resultant treatment advances
will be immediately and broadly generalizable (25). If any
additional objective confirmation is desired, perhaps it
should be with cardiopulmonary exercise testing, which
reliably quantifies the central feature of chronic HFpEF,
excludes others such as primary pulmonary disease, forces
no assumptions regarding mechanisms, and can assess
reserve capacity of both cardiac and peripheral components
of the exercise response (15–17,20,21,30).
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